



Advances in Vaccine Development and Immunotherapies

Guest Editors:

Dr. Vita Golubovskaya

1. Promab Biotechnologies, 2600 Hilltop Drive, Building B, C348, Richmond, CA 94803, USA
2. Department of Medicine, University of Oklahoma Health Sciences Center, Andrews Academic Tower, 800 Stanton L. Young Blvd, Oklahoma City, OK 73104, USA

Dr. Emmanuel Datan

Vascular Program, Institute for Cell Engineering and Department of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Deadline for manuscript submissions:

closed (10 March 2021)

Message from the Guest Editors

Dear Colleagues,

During Covid-19 pandemic, it is very important to submit reports on vaccine development. Vaccine development can include vaccines against viral diseases, dendritic cell vaccines against cancer or other diseases. In addition, this issue can involve recent development of new immunotherapies against cancer such as chimeric antigen receptor (CAR) T cells therapies, checkpoint inhibitors, monoclonal antibodies, bi-specific antibodies, and combination therapies. The reports on pre-clinical vaccine development, clinical trial data and reviews can be submitted to this issue.

Dr. Vita Golubovskaya
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)